Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Total Liabilities (2019 - 2026)

Alx Oncology Holdings' Total Liabilities history spans 5 years, with the latest figure at $52.8 million for Q4 2023.

  • On a quarterly basis, Total Liabilities rose 22.81% to $52.8 million in Q4 2023 year-over-year; TTM through Dec 2023 was $52.8 million, a 22.81% increase, with the full-year FY2023 number at $52.8 million, up 22.81% from a year prior.
  • Total Liabilities hit $52.8 million in Q4 2023 for Alx Oncology Holdings, up from $51.4 million in the prior quarter.
  • Over the last five years, Total Liabilities for ALXO hit a ceiling of $75.9 million in Q1 2020 and a floor of $6.2 million in Q4 2020.
  • Historically, Total Liabilities has averaged $31.6 million across 5 years, with a median of $29.7 million in 2022.
  • Biggest five-year swings in Total Liabilities: crashed 83.43% in 2020 and later surged 175.95% in 2021.
  • Tracing ALXO's Total Liabilities over 5 years: stood at $11.0 million in 2019, then plummeted by 43.31% to $6.2 million in 2020, then surged by 175.95% to $17.1 million in 2021, then skyrocketed by 151.11% to $43.0 million in 2022, then grew by 22.81% to $52.8 million in 2023.
  • Business Quant data shows Total Liabilities for ALXO at $52.8 million in Q4 2023, $51.4 million in Q3 2023, and $33.2 million in Q2 2023.